ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "registry"

  • Abstract Number: 0820 • ACR Convergence 2022

    Therapeutic Practices and Outcomes of Chronic Sarcoidosis Arthropathy in the United States: A Nationwide Registry Study

    Diala Alawneh1, Moustafa Younis2, Bashar Alzghoul2, Christian Ascoli1, Tricha Shivas3, Mary McGowan3, Khaldoon Alawneh4, Divya Patel2, Israel Rubinstein1 and Nadera Sweiss1, 1University of Illinois at Chicago, Chicago, IL, 2University of Florida, Gainesville, FL, 3Foundation for Sarcoidosis Research, Chicago, IL, 4Jordan University of Science and Technology, Irbid, Jordan

    Background/Purpose: Chronic arthropathy is a rare manifestation of sarcoidosis reported in only 0.2% of patients. However, treatment is challenging because no general consensus regarding appropriate…
  • Abstract Number: 1752 • ACR Convergence 2022

    Cancer Risk in Patients with Rheumatic Diseases Exposed to Different Biologic and Targeted Synthetic DMARDs in Real World Clinical Practice: Data from BIOBADASER

    Isabel Castrejon1, Juan Molina2, Carolina Perez-Garcia3, Paloma Vela-Casampere4, Cesar Diaz-Torne5, Cristina Bohorquez6, Juan Maria Blanco-Madrigal7 and Fernando Sanchez-Alonso8, 1Hospital Universitario Gregorio Marañón, Madrid, Spain, 2Hospital General Universitario Gregorio Marañón, Madrid, Spain, 3Department of Rheumatology, Hospital del Mar, Barcelona, Spain, 4Hospital General Universitario Alicante, Alicante, Spain, 5Department of Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 6University Hospital Príncipe de Asturias, Immune System Diseases-Rheumatology Service, Alcalá de Henares, Madrid, Spain, 7Department of Rheumatology, Hospital de Basurto, Bilbao, Spain, 8Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain

    Background/Purpose: Extensive evidence has confirmed no increased risk of cancer associated to either conventional synthetic DMARDs or anti-TNF in patients with rheumatic diseases. The risk…
  • Abstract Number: 0850 • ACR Convergence 2022

    Outcomes of Patients with Juvenile Idiopathic Arthritis Following Failure of Initial Tumor Necrosis Factor Inhibitor Medication in the Childhood Arthritis and Rheumatology Research Alliance Registry

    Melissa Mannion1, Shahla Amin2, Stephen Balevic3, Colleen Correll4, Timothy Beukelman1 and , for the CARRA Registry Investigators5, 1University of Alabama at Birmingham, Birmingham, AL, 2Childhood Arthritis and Rheumatology Research Alliance, Washington, DC, 3Duke University, Durham, NC, 4University of Minnesota, Minneapolis, MN, 5CARRA, Washington, DC

    Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are the most commonly used first biologics to treat juvenile idiopathic arthritis (JIA), but it is unknown what subsequent…
  • Abstract Number: 1842 • ACR Convergence 2022

    Vaccination in Patients with Autoinflammatory Periodic Syndromes Under Canakinumab – Safety Data Interim Analysis of the RELIANCE Registry

    Jasmin B. Kuemmerle-Deschner1, Joerg Henes2, Birgit Kortus-Goetze3, Tilmann Kallinich4, Prasad T. Oommen5, Juergen Rech6, Tobias Krickau7, Frank Weller-Heinemann8, Gerd Horneff9, Ales Janda10, Ivan Foeldvari11, Catharina Schuetz12, Frank Dressler13, Michael Borte14, Markus Hufnagel15, Florian Meier16, Michael Fiene17, Julia Weber-Arden18 and Norbert Blank19, 1Department of Pediatrics, Division of Pediatric Rheumatology, University Hospital Tübingen, Tübingen, Germany, 2Center for Interdisciplinary Clinical Immunology, Rheumatology and Auto-inflammatory Diseases (INDIRA), University Hospital Tübingen, Tübingen, Germany, 3Division of Nephrology, University of Marburg, Marburg, Germany, 4Charité - Universitätsmedizin Berlin, Nuremberg, Germany, 5Clinic of Pediatric Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, 6University Clinic Erlangen, Erlangen, Germany, 7Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Pediatrics, Erlangen, Germany, 8Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany, 9Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, 10Department of Pediatrics, University Hospital Ulm, Ulm, Germany, 11Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, 12Pediatrics, Medizinische Fakultaet Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany, 13Division of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany, 14ImmunoDeficiencyCenter Leipzig (IDCL), Hospital St. Georg gGmbH Leipzig, Germany, Leipzig, Sachsen, Germany, 15Division of Pediatric Infectious Diseases and Rheumatology, Department of Pediatrics and Adolescent Medicine, University Hospital Medical Center Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany, 16Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt, Germany, 17Rheumatology Center Greifswald, Greifswald, Germany, 18Novartis Pharma GmbH, Nuernberg, Germany, 19Rheumatology, University Hospital Heidelberg, Heidelberg, Germany

    Background/Purpose: Treatment of autoinflammatory periodic syndromes with the interleukin-1β inhibitor canakinumab (CAN) has been shown to be safe and effective in clinical trials and in…
  • Abstract Number: 0855 • ACR Convergence 2022

    Change in Short Term Outcomes Following Tolerated Disease Activity Level for Individuals with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry

    Melissa Mannion1, Fenglong Xie1, Timothy Beukelman1, Jeffrey Curtis2 and , for the CARRA Registry Investigators3, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Hoover, AL, 3CARRA, Washington, DC

    Background/Purpose: Current recommendations suggest treatment escalation for juvenile idiopathic arthritis (JIA) until the disease activity target is reached, ideally inactive or low disease activity. Our…
  • Abstract Number: 1992 • ACR Convergence 2022

    Burden of Pain for Patients in the CorEvitasTM Rheumatoid Arthritis Registry

    Joshua Baker1, J Morel Symons2, Jud C Janak3, Page Moore3, Elizabeth Kohl3, Bernice Gershenson3, Oksana Pugach3, Dave Webb4, Alan A Martin4, Didier Saurigny5 and Marguerite Bracher5, 1University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, 2GlaxoSmithKline, Collegeville, PA, 3CorEvitas, LLC, Waltham, MA, 4GlaxoSmithKline, Brentford, United Kingdom, 5GlaxoSmithKline, Stevenage, United Kingdom

    Background/Purpose: Pain is a hallmark symptom of RA that impacts patients' quality of life and informs therapeutic decisions that aim to reduce joint inflammation and…
  • Abstract Number: 0888 • ACR Convergence 2022

    Cardiovascular and Thromboembolic Events in Rheumatoid Arthritis Patients Before and After Initiation of a First Advanced Therapy. Data from the University of Sherbrooke Registry of Advanced Therapies (USRAT)

    Nathalie Carrier1, Sophie Roux2, Hugues Allard-Chamard2 and Gilles Boire3, 1Centre intégré universitaire de santé et services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS), Sherbrooke, QC, Canada, 2Université de Sherbrooke and Centre intégré universitaire de santé et services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS), Sherbrooke, QC, Canada, 3Universite de Sherbrooke, Sherbrooke, QC, Canada

    Background/Purpose: Uncontrolled inflammation in rheumatoid arthritis (RA) patients increases the risk for incident Ischemic Heart Disease (IHD) and venous thromboembolic (TE) events. Reducing inflammation using…
  • Abstract Number: 1999 • ACR Convergence 2022

    Patient-Reported Outcomes in Rheumatoid Arthritis Correlate with Clinical Disease Activity Index Response in the Study to Accelerate Information of Molecular Signatures (AIMS)

    Vibeke Strand1, Emelly Rusli2, Lixia Zhang2, Christina Le-Short2, Alix Arnaud2, Johanna Withers3 and Sam Asgarian2, 1Stanford University School of Medicine, Stanford, CA, 2Scipher Medicine Corporation, Waltham, MA, 3Scipher Medicine Corportaion, Waltham, MA

    Background/Purpose: Rheumatoid arthritis (RA) treatment response is typically defined using clinician-reported scores and patient global assessments of disease activity (PtGA), but patients may have a…
  • Abstract Number: 0087 • ACR Convergence 2021

    TNF Inhibitors and the Risk of Adverse COVID-19 Outcomes in Patients with Immune-Mediated Inflammatory Disease: Pooled Data from Three Global Registries

    Zara Izadi1, Erica Brenner2, Satveer Mahil3, Nick Dand4, Zenas Yiu5, Mark Yates4, Ryan Ungaro6, Xian Zhang2, Manasi Agrawal6, Jean-Frederic Colombel7, Milena Gianfrancesco1, Kimme Hyrich5, Anja Strangfeld8, Loreto Carmona9, Elsa Frazão Mateus10, Saskia Lawson-Tovey5, Eva Klingberg11, Giovanna Cuomo12, Marta Caprioli13, Rene-Marc FLIPO14, Ana Rita Cruz-Machado15, Carolina Mazeda16, Rebecca Hasseli17, Alexander Pfeil18, Hanns-Martin Lorenz19, Laura Trupin20, Stephanie Rush1, Patricia Katz1, Gabriela Schmajuk1, Lindsay Jacobsohn21, Andrea Seet1, Samar Al Emadi22, Leanna Wise23, Emily Gilbert24, Ali Duarte-Garcia25, Maria Valenzuela-Almada26, Carolina Isnardi27, Rosana Quintana27, Enrique Soriano28, Tiffany Hsu29, Kristin D'Silva30, Jeffrey Sparks31, Naomi Patel30, Viviane de Souza32, Licia Maria Henrique Mota33, Ana Paula Reis34, Zachary S. Wallace35, Suleman Bhana36, Wendy Costello37, Rebecca Grainger38, Jonathan Hausmann39, Jean Liew40, Emily Sirotich41, Paul Sufka42, Philip Robinson43, Pedro Machado44, Christopher Griffiths45, Jonathan Barker4, Catherine smith4, Jinoos Yazdany1 and Michael Kappelman2, 1University of California San Francisco, San Francisco, CA, 2University of North Carolina at Chapel Hill, Chapel Hill, NC, 3St John’s Institute of Dermatology, London, United Kingdom, 4King's College London, London, United Kingdom, 5University of Manchester, Manchester, United Kingdom, 6Icahn School of Medicine at Mount Sinai, New York, NY, 7MD, New York, NY, 8Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, 9Instituto de Salud Musculoesqueltica (InMusc), Madrid, Spain, 10Liga Portuguesa Contra as Doenças Reumáticas (LPCDR), Lisbon, Portugal, 11University of Gothenburg, Gothenburg, Sweden and Sahlgrenska University Hospital, Gothenburg, Sweden, 12Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy, 13IRCCS Humanitas Research Hospital, Milan, Italy, 14Rheumatology Department, Lille University Hospital, Lille, France, 15Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Center; Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, 16Rheumatology Department - Centro Hospitalar do Baixo Vouga and Ibimed, Institute for Biomedicine, University of Aveiro, Aveiro, Portugal, 17Justus-Liebig-University Giessen, Bad Nauheim, Germany, 18Friedrich Schiller University Jena, Jena, Germany, 19University Hospital Heidelberg Germany, Heidelberg, Germany, 20UC San Francisco, San Francisco, CA, 21University of California San Francisco, Antioch, CA, 22Hamad medical corporation, Doha, Qatar, 23LAC+USC/Keck Medicine of USC, Pasadena, CA, 24Mayo Clinic, Jacksonville, FL, 25Mayo Clinic, Rochester, MN, 26Division of Rheumatology, Mayo Clinic, Rochester, MN, 27Argentine Society of Rheumatology, Buenos Aires, Argentina, 28Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 29Brigham and Women's Hospital, Jamaica Plain, MA, 30Massachusetts General Hospital, Boston, MA, 31Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 32UFJF, JUIZ DE FORA, Brazil, 33Universidade de Brasília, Brasilia, Brazil, 34Centro Universitrio de Braslia- UniCEUB, Brasilia, Brazil, 35Harvard Medical School, Boston, MA, 36Crystal Run Health, Montvale, NJ, 37Irish Children's Arthritis Network, Bansha, Ireland, 38University of Otago, Wellington, New Zealand, 39Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, 40Boston University, Boston, MA, 41McMaster University, Hamilton, ON, Canada, 42HealthPartners, Eagan, MN, 43University of Queensland School of Clinical Medicine, Brisbane, Australia, 44Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, 45University of Manchester, Manchester Centre for Dermatology Research, Manchester, United Kingdom

    Background/Purpose: While tumor necrosis factor inhibitors (TNFi) are widely prescribed globally due to their high efficacy across immune-mediated inflammatory diseases (IMIDs), the impact of COVID-19…
  • Abstract Number: 0802 • ACR Convergence 2021

    Infection in Rheumatoid Arthritis Patients Treated with Golimumab

    Louis Bessette1, Proton Rahman2, John Kelsall3, Jane Purvis4, Emmanouil Rampakakis5, Allen Lehman6, Meagan Rachich6, Francois Nantel7 and Odalis Asin-Milan6, 1Laval University, Québec City, QC, Canada, 2Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, 3Providence Health Care, Vancouver, BC, Canada, 4Peterborough Education, Peterborough, ON, Canada, 5JSS Medical Research, Montréal, QC, Canada, 6Janssen Inc., Toronto, ON, Canada, 7., Montreal, ON, Canada

    Background/Purpose: Biologic use in RA is a well-characterized risk factors for infections. The aim of this analysis was to characterize the incidence of infection in…
  • Abstract Number: 1830 • ACR Convergence 2021

    Discontinuation of Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis and Psoriasis

    Sophia Wolfe1, Elizabeth Cheng2, Kavya Ganuthula1, Meika Fang3, Gail Kerr4, Jessica Walsh5, Elizabeth Chang6, Siba Raychaudhuri7, Kyle Brees2, Robert Dellavalle1, Andreas Reimold8 and Liron Caplan9, 1Rocky Mountain Regional VAMC/University of Colorado School of Medicine, Aurora, CO, 2Rocky Mountain Regional VAMC, Aurora, CO, 3David Geffen School of Medicine at UCLA/West Los Angeles Veterans Affairs Medical Center (VAMC), Los Angeles, CA, 4Washington D.C., Veterans Affairs Medical Center (VAMC)/Georgetown and Howard Universities, Washington, DC, 5Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT, 6Phoenix VAMC, Phoenix, AZ, 7Sacramento Veterans Affairs Medical Center (VAMC)/University of California-Davis Health, Davis, CA, 8University of Texas – Southwestern Medical Center/Dallas Veterans Affairs Medical Center (VAMC), Dallas, TX, 9Rocky Mountain Regional Veterans Affairs Medical Center (VAMC)/University of Colorado School of Medicine, Aurora, CO

    Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease of the joints and skin that affects 1/1000 people in the US. Tumor necrosis factor-alpha (TNF-α)…
  • Abstract Number: 0116 • ACR Convergence 2021

    COVID-19 mRNA Vaccine Side Effects Among Individuals with Rheumatic Disease

    Kaleb Michaud1, Adam Cornish2, Alison Freifeld1, Patricia Katz3 and Kristin Wipfler2, 1University of Nebraska Medical Center, Omaha, NE, 2FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 3University of California San Francisco, San Francisco, CA

    Background/Purpose: Over 135 million Americans were fully vaccinated to COVID-19 by June 2021, yet there was a paucity of data on side effects for those…
  • Abstract Number: 0813 • ACR Convergence 2021

    Improvement in Clinical Disease Activity and Patient-Reported Outcomes After 6 Months of Treatment with Abatacept, Stratified by Line of Therapy, in Patients with RA: Results from a Large, US, National Observational Study

    Leslie Harrold1, Keith Wittstock2, Sheila Kelly2, Sang Hee Park2, Xue Han2, Ying Shan1, Carla Roberts-Toler1, Nicole Middaugh1 and Vadim Khaychuk2, 1CorEvitas, LLC, Waltham, MA, 2Bristol Myers Squibb, Princeton, NJ

    Background/Purpose: RA is more responsive to treatment in the early stages of disease, and early treatment may lead to better long-term outcomes.1,2 Data on the…
  • Abstract Number: 1831 • ACR Convergence 2021

    Predictors of Response, Adverse Events and Treatment Retention in Psoriatic Arthritis Patients Treated with Golimumab in a Prospective, Observational Registry

    Proton Rahman1, Isabelle Fortin2, Regan Arendse3, Derek Haaland4, Arthur Karasik5, Maqbool Sheriff6, Emmanouil Rampakakis7, Meagan Rachich8, Francois Nantel9, Allen Lehman8 and Odalis Asin-Milan8, 1Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, 2CREQ, Rimouski, QC, Canada, 3University of Saskatchewan, Saskatoon, SK, Canada, 4McMaster University, Hamilton, Ontario and The Waterside Clinic, Oro Medonte, ON, Canada, 5Arthur Karasik Medicine Professional Corporation, Toronto, ON, Canada, 6Nanaimo Regional Hospital, Nanaimo, BC, Canada, 7JSS Medical Research, Montréal, QC, Canada, 8Janssen Inc., Toronto, ON, Canada, 9., Montréal, QC, Canada

    Background/Purpose: The Biologic Treatment Registry Across Canada (BioTRAC) was a prospective, observational registry that enrolled psoriatic arthritis (PsA) patients treated with subcutaneous golimumab (GLM) between…
  • Abstract Number: 0190 • ACR Convergence 2021

    Long-term Safety of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes – Interim Analysis of the RELIANCE Registry

    Jasmin Kuemmerle-Deschner1, Jorg Henes2, Birgit Kortus-Goetze3, Tilmann Kallinich4, Prasad T. Oommen5, Juergen Rech6, Frank Weller-Heinemann7, Gerd Horneff8, Ivan Foeldvari9, Aleš Janda10, Catharina Schuetz11, Frank Dressler12, Michael Borte13, Markus Hufnagel14, Axel Braner15, Florian Meier16, Michael Fiene17, Julia Weber-Arden18 and Norbert Blank19, 1Pediatric Rheumatology and Autoinflammatory Reference Center, University Children's Hospital Tuebingen, Tuebingen, Germany, 2University Hospital Tuebingen, Tuebingen, Germany, 3Division of Nephrology, University of Marburg, Marburg, Germany, 4Charité University Medicine, Nuremberg, Germany, 5Clinic of Pediatric Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, 6Friedrich-Alexander University (FAU) Erlangen-Nuernberg and Universitaetsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology, Germany, Erlangen, Germany, 7Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany, 8Paediatric Rheumatology International Trials Organisation (PRINTO), Sankt Augustin, Germany, 9Hamburger Zentrum fuer Kinder- und Jugendrheumatologie, Hamburg, Germany, 10Department of Pediatrics, University Hospital Ulm, Ulm, Germany, 11Pediatrics, Medizinische Fakultaet Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany, 12Division of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany, 13ImmunoDeficiencyCenter Leipzig (IDCL), Hospital St. Georg gGmbH Leipzig, Leipzig, Germany, 14Division of Pediatric Infectious Diseases and Rheumatology, Department of Pediatrics and Adolescent Medicine, University Hospital Medical Center Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany, 15Department of Medicine II, Rheumatology, University Hospital Frankfurt, Germany, Frankfurt a.M., Germany, 161 Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany 2 Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt am Main, Germany, Frankfurt a.M., Germany, 17Department of Internal Medicine, District Hospital Demmin, Demmin, Germany, 18Novartis Pharma GmbH, Nuremberg, Germany, 19Rheumatology, University Hospital Heidelberg, Eppelheim, Germany

    Background/Purpose: Autoinflammatory periodic fever syndromes (PFS) are characterized by severe systemic and organ inflammation. In clinical trials, successful treatment was achieved with the interleukin-1β inhibitor…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology